Amphastar Pharmaceuticals, Inc. 10-Q filing
Filed 2025-11-06 · Report date 2025-09-30 · 2025
Filing metadata
- Accession number
- 0001297184-25-000064
- Form type
- 10-Q
- CIK
- 0001297184
- Primary document
- https://www.sec.gov/Archives/edgar/data/1297184/000129718425000064/amph-20250930x10q.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Amphastar Pharmaceuticals, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $536.8M | - | - |
| Cost Of Revenue | $266.4M | - | - |
| Gross Profit | $270.4M | - | - |
| Operating Income | $104.8M | - | - |
| Net Income | $73.7M | - | - |
| Eps Basic | 1.57 | - | - |
| Eps Diluted | 1.52 | - | - |
| Cash And Equivalents | $216.3M | - | - |
| Total Assets | $1.7B | - | - |
| Total Liabilities | $889.5M | - | - |
| Operating Cash Flow | $123.3M | - | - |
| Capital Expenditures | $26.6M | - | - |